ANO1 and breast carcinoma: Before it was identified as a CaCC, TMEM16A had been found to be amplified in oral cancer, head and neck squamous cell carcinoma (HNSCC), gastrointestinal stromal tumor (GIST), breast cancer, and esophageal squamous cell (ESCC) cancer under other names such as FLJ10261, TAOS1 (tumor amplified and overexpressed sequence 1) and DOG1 (discovered on GISTs protein 1) [37–41].